Drug intelligence / Profile preview

ENERGI-F703DFU

Development stage: Unknown
Lead developer: Energenesis Biomedical
Modality: Small Molecules
Administration: Topical

Overview

ENERGI-F703DFU is a topical gel formulation of a first-in-class small molecule activator of 5'-AMP-activated protein kinase (AMPK). Developed by Energenesis Biomedical and licensed to Pharma Bavaria International for multi-regional commercialization, the drug is currently in Phase 3 clinical trials for the treatment of diabetic foot ulcers (DFU). By activating AMPK, ENERGI-F703DFU aims to restore cellular energy balance, stimulate angiogenesis, and promote the migration and proliferation of keratinocytes and fibroblasts, thereby accelerating the healing of chronic diabetic wounds.

Targets

AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on ENERGI-F703DFU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENERGI-F703DFU.

Explore the full profile